Citations

Clear

76 citation(s) found for "Mangold, Aaron".

Search and Retrieval in Dermatology Atlases of Histopathology Images for Risk Stratification of Cutaneous Squamous Cell Carcinoma
Alabtah, Ghazal, Alsaafin, Areej , Shafique, Abubakr , Hemati, Sobhan, Choudhary, Anirudh , DiCaudo, David J. , Nelson, Steve A., Stockard, A., Leibovit-Reiben, Zach, Zhang, Nan, Murphree, Dennis H. , Comfere, Nneka I. , Tizhoosh, H. R., Alfasly, Saghir , Iyer, Ravishankar K. , Stockard, Alyssa , Leibovit‐Reiben, Zachary , Kalari, Krishna R. , Mangold, Aaron R.

Mayo Clinic

No container title available | January 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.02.26343356 Get It

Abstract Cutaneous squamous cell carcinoma (cSCC) poses significant clinical challenges due to its rising incidence and potential for metastasis. Histopathologic risk stratification is further limited by substantial inter-observer variability. Unsupervised AI approaches based on content-based image retrieval offer scalable and interpretable decision support for diagnostic pathology. The objective of this study was to evaluate the use of image retrieval within histopathology atlases to stratify cSCC tumor differentiation from whole-slide images (WSIs), while comparing different patch selection and feature extraction strategies. This retrospective study included 552 archived WSIs comprising 385 well-differentiated, 102 moderately differentiated, and 66 poorly differentiated cases collected across Mayo Clinic sites in Arizona, Florida, and Minnesota. Image atlases were constructed using multiple patch aggregation strategies (Mosaic, Collage, and Montage) and deep learning encoders (KimiaNet, PathDino, and H-Optimus-0). A leave-one-WSI-out evaluation framework was used to assess differentiation classification performance using accuracy, specificity, sensitivity, and F1 score. Mosaic combined with KimiaNet achieved the highest Top-1 accuracy (74.9%) and specificity (92.6%), while Mosaic with H-Optimus-0 yielded the best Top-5 accuracy (79.0%) and macro-F1 score (62.6%). Collage combined with KimiaNet produced the highest Top-5 specificity (99.5%). The generalizability of the evaluated AI models varied across hospitals, reflecting differences in imaging protocols, staining practices, and patient populations. Overall, unsupervised image search and retrieval provides effective, annotation-free support for cSCC differentiation and has the potential to enhance dermatopathology workflows when appropriate combinations of patch selection and feature ex-traction methods are employed.
Excision With Total Margin Control Versus Vertical Section Margin Assessment for NCCN Very High-Risk Cutaneous Squamous Cell Carcinoma
Wang, David M., Ran, Nina A., Granger, Emily E., Koyfman, Shlomo, Vidimos, Allison, Wysong, Ashley, Carr, David R., Shahwan, Kathryn T., Hirotsu, Kelsey E., Carucci, John A., Carter, Joi B., Cañueto, Javier, Girardi, Fabio M., Mangold, Aaron R., Srivastava, Divya, Nijhawan, Rajiv I., Brodland, David G., Zitelli, John A., Willenbrink, Tyler J., Ruiz, Emily S., Mangold, Aaron R. , Hirotsu, Kelsey E. , Mangold, A R , Wang, David M., Ran, Nina A., Granger, Emily E., Koyfman, Shlomo, Vidimos, Allison, Wysong, Ashley, Carr, David R., Shahwan, Kathryn T., Carucci, John A., Carter, Joi B., Cañueto, Javier, Girardi, Fabio M., Srivastava, Divya, Nijhawan, Rajiv I., Brodland, David G., Zitelli, John A., Willenbrink, Tyler J., Ruiz, Emily S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 531-537

10.6004/jnccn.2025.7072 | PMID 41671454 Get It

Background: Among the 1.5 million cases of cutaneous squamous cell carcinoma (cSCC) diagnosed annually in the United States, a subset of aggressive tumors recur or metastasize. Treatment options include total margin-controlled surgery, such as Mohs micrographic surgery or other forms of peripheral and deep en face margin assessment (MMS/PDEMA), and standard excision with postoperative vertical section margin assessment (SEVMA). NCCN Guidelines recommend MMS/PDEMA for the management of cSCC classified as very high risk based on NCCN risk stratification criteria. This study aims to validate the recommendation of MMS/PDEMA as the preferred surgical approach for NCCN very high-risk cSCCs, using data from a multicenter, multinational cohort. Methods: A multicenter cohort study was conducted across 12 sites, including 10 in the United States, 1 in Spain, and 1 in Brazil, comprising 2,752 primary NCCN very high-risk cSCCs treated with MMS/PDEMA or SEVMA. Propensity score–weighted analysis was used to balance baseline characteristics. Outcomes included local recurrence (LR), nodal metastasis (NM), distant metastasis (DM), and disease-specific death (DSD). Results: After balancing baseline characteristics, SEVMA was associated with a 2-fold higher rate of poor outcomes, including recurrence, metastasis, and DSD, compared with MMS/PDEMA. The 3-year cumulative incidence of poor outcomes was higher for SEVMA: LR (12.5% vs 5.9%), NM (11.6% vs 6.0%), DM (4.3% vs 1.9%), and DSD (6.2% vs 3.3%). Conclusions: This study supports the NCCN recommendation of MMS/PDEMA for NCCN very high-risk cSCC, showing reduced recurrence, metastasis, and cSCC-specific mortality compared with SEVMA.
Immunoediting restricts clonal neoantigens in primary human tumors 2606
Borden, Elizabeth S. , Hughes, Alysia , Ma, Tao , Mangold, Aaron R. , Gutenkunst, Ryan N. , LaFleur, Bonnie , Buetow, Kenneth H. , Mangold, A R , Castellano, David , Li, Xing , Wilson, Melissa Ann , Hastings, Karen Taraszka

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.507 Get It

Abstract Description Evidence consistent with immunoediting in human cancer has been identified through associative studies. To provide direct evidence that differences in the neoantigen profile are immune-mediated, we compared the neoantigen profiles of cutaneous squamous cell carcinoma (cSCC) from immunocompetent and immunosuppressed patients. Despite consistency in the overall mutational burden and signature, immunocompetent patients have a lower clonal mutational burden compared to immunosuppressed patients. Furthermore, clonal mutations in cSCC from immunocompetent patients have a lower proportion of neoantigens predicted to bind MHC class I, supporting the role of the immune system in shaping the neoantigen profile. In single-cell RNA sequencing of intratumoral CD8+ T cells from a separate cohort of cSCC from immunocompetent and immunosuppressed patients, we observe an increase in exhausted CD8+ T cells in tumors from immunocompetent patients, suggesting an explanation for the persistence of binding neoantigens subclonally. Finally, we compare clonal and subclonal neoantigens as an unbiased screen for characteristics associated with neoantigen immunogenicity. Neoantigens with a large increase in predicted MHC class I binding relative to the normal peptide are enriched in subclonal neoantigens in immunocompetent patients. Overall, this work supports the immune system’s role in sculpting the neoantigen profile of cSCC. Funding Sources Supported by American Cancer Society - Simone Charitable Foundation - Discovery Boost Grant, AZ-DBG-23-1151311-01-IBCD; NIH F30CA281056; R35GM149235 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Structural changes from wild-type define tumor-rejecting neoantigens
Adams, Anngela C. , Macy, Anne M. , Borden, Elizabeth S. , Herrmann, Lauren M , Brambley, Chad A. , Hughes, Alysia , Roe, Denise J. , Mangold, Aaron R. , Buetow, Kenneth H. , Baker, Brian M. , Hastings, Karen Taraszka , Nikolich, Janko Z , Hastings, K Taraszka , Mangold, A R , Sonar, Sandip Ashok , Ma, Tao , Li, Xing , Nikolich‐Žugich, Janko , Wilson, Melissa Ann

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 23, 2025 | Volume: 13 | Issue: 10 | Pages: e013148

10.1136/jitc-2025-013148 | PMID 41125532 Get It

Background Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). Only a small portion of neoantigens prioritized by current methods elicit effective T cell responses, demonstrating the critical need for improved criteria for the prediction of tumor-rejecting neoantigens. Methods Publicly available human cSCC datasets were used to assess the frequency of shared mutations between patients. A transplantable ultraviolet light-induced mouse model of cSCC was generated. The mutational signature and driver mutations in the mouse model were compared with human tumors. Neoantigens were prioritized in the mouse model, and tumor-rejecting neoantigens were identified through (enzyme-linked immunosorbent spot (ELISpot) and in vivo prophylactic vaccination. Binding of the neoantigens and corresponding wild-type peptides to major histocompatibility complex (MHC) class I was determined. Structural modeling of peptide:MHC complexes was performed to assess for changes in structural characteristics of the neoantigens relative to the wild-type peptides. Results A minority of human cSCC tumors shared neoantigens. The mouse cSCC model recapitulated the mutational signature and driver mutations found in human disease and was constrained by CD8 T cells. Two MHC class I neoantigens were identified in the mouse model that constrained cSCC growth. One tumor-rejecting neoantigen exhibited improved MHC binding, and the other had increased solvent accessibility of the mutated residue, compared with wild-type. Across known neoantigens that do not impact MHC binding, increased exposure of the mutated residue distinguished tumor-rejecting from non-immunogenic neoantigens. Conclusions Given the paucity of shared mutations, this work supports the need for personalized neoantigen vaccines in cSCC. To facilitate further discovery, we provide a clinically relevant mouse cSCC model with two defined neoantigens that mediate tumor rejection. Structural changes in the exposure of features that promote T cell receptor recognition defined tumor-rejecting neoantigens. Incorporation of structural modeling to predict changes in T cell receptor accessibility is anticipated to improve the selection of neoantigens for inclusion in personalized cancer vaccines.
Dual TRBC1-CD3 Immunohistochemistry Shows High Diagnostic Utility in Differentiating Mycosis Fungoides/Sezary Syndrome From Reactive Inflammatory Dermatoses in Skin Biopsies
Lewis, Natasha , DiCaudo, David J. , Zhou, Jiehao , Howard, Matthew T., Mangold, Aaron R. , Lewis, Natasha E , Rosenthal, Allison C, Mangold, A R , Jevremović, Dragan , Law, Mark E., Rosenthal, Allison , Gibson, Sarah E.

Mayo Clinic

American Journal of Surgical Pathology | October 3, 2025 | Volume: 50 | Issue: 1 | Pages: 1-11

10.1097/pas.0000000000002474 | PMID 41039797 Get It

Evaluation of T-cell receptor (TCR) β-chain constant region 1 (TRBC1) expression is an alternative T-cell clonality assessment method. However, evaluation of TRBC1 immunohistochemistry (IHC) for distinguishing mycosis fungoides (MF)/Sezary syndrome (SS) from reactive inflammatory infiltrates in skin is incomplete. We evaluated the utility of a novel dual TRBC1-CD3 IHC stain in skin biopsies with MF/SS (n=40), reactive (n=24), or atypical T-cell infiltrates indeterminant for MF/SS (n=9). Twenty of 24 reactive cases showed clear polytypic TRBC1 expression (median percent TRBC1 positivity among CD3-positive T cells [%TRBC1+] 50% in dermis, 42.5% in epidermis among all cases), while 34/40 MF/SS were clearly monotypic (%TRBC1+ either ≤20% or ≥85%) (sensitivity 85.0%, specificity 91.7%, positive predictive value 94.4%, negative predictive value 78.6%). Discordance between TRBC1 expression and diagnosis was associated with few neoplastic/monotypic T cells and/or lack of physical separation between neoplastic and non-neoplastic populations. Among patch/plaque MF/SS, TRBC1 showed similar diagnostic sensitivity (80.0% vs. 86.7%) and high categorical correlation (monotypic vs. not monotypic, 80%) with TCR gene rearrangement results. TRBC1 interpretation was reproducible, with ≥2/3 and 3/3 pathologists rendering identical interpretations in 100% and 86% of cases, respectively, after independent review and 100% agreement following collective review. Digital image analysis confirmed visual %TRBC1+ accuracy ( r =0.9749, P <0.0001). On the basis of these results, we propose %TRBC1+ cutoffs of <25% or >75% for establishing T-cell monotypia in skin. Considering such thresholds, TRBC1-CD3 evaluation facilitated diagnostic refinement in 7/9 (78%) atypical cases. Overall, TRBC1-CD3 IHC clearly and rapidly aids diagnosis of cutaneous T-cell proliferations.
Validation of Current Staging Systems in HNCSCC : A Multinational Cohort Study
Girardi, Fábio Muradás , Machado, Cristian David Cardona , Wysong, Ashley, Ran, Nina A., Granger, Emily , Koyfman, Shlomo A. , Vidimos, Allison T. , Carr, David R. , Shahwan, Kathryn T., Hirotsu, Kelsey E. , Carter, Joi B., Mangold, Aaron R. , Brodland, David G., Zitelli, John A. , Willenbrink, Tyler J., Jambusaria‐Pahlajani, Anokhi , Nijhawan, Rajiv I. , Ruiz, Emily S. , Cañueto, Javier , Granger, Emily E , Shahwan, Kathryn T , Willenbrink, Tyler J , Mangold, A R , Wagner, Vivian Petersen , Wysong, Ashley , Carr, David R., Carucci, John A. , Srivastava, Divya

Mayo Clinic

Head & Neck | July 25, 2025 | Volume: 47 | Issue: 12 | Pages: 3385-3393

10.1002/hed.28259 | PMID 40709408 Get It

ABSTRACT Importance Risk stratification of cutaneous squamous cell carcinoma (CSCC) is central to effective management. Despite advancements in the 8th edition of the American Joint Committee on Cancer (AJCC8) staging system, the distinctiveness of T‐stages remains limited. Objective To evaluate the effectiveness of the Brigham and Women's Hospital (BWH) and the AJCC8 staging systems in predicting poor outcomes in head and neck (HN) CSCC. Design A retrospective, multinational cohort study of CSCCs diagnosed between January 10, 1991, and December 31, 2023. Setting Twelve centers across the United States (10), Spain (1), and Brazil (1). Participants Patients with invasive CSCC who underwent curative‐intent surgical treatment. Exclusions included cases of lip CSCC, cases with prior HN cancer with associated regional disease, patients with a history of chemotherapy/radiotherapy for other HN neoplasms, and recurrent primary tumors. Exposure Tumors were staged according to both the AJCC8 TNM staging system and the BWH tumor classification. Main Outcomes and Measures Local recurrence (LR), nodal recurrence (NR), distant recurrence (DR), and disease‐specific death (DSD). Results A total of 9852 excised tumors from 3168 patients were included. The 2 systems had comparable monotonicity and homogeneity. Significant differences could be observed in 5‐year cumulative incidence for DSD in both BWH and AJCC8, and also for LR in BWH. Higher T‐stages exhibited similar curves regarding NR and DR for both AJCC8 and BWH staging systems. Overall, we observed high specificity and NPV, low sensitivity and PPV, and moderately high c‐indices for both the BWH and AJCC8 staging systems in predicting the main outcomes for HNCSCC. Conclusion and Relevance Current AJCC8 and BWH staging systems can accurately predict survival in HNCSCC, although there are still important characteristics to be addressed in future staging systems for better stratification according to the other main outcomes.
Assessment of a Deep Learning Model Trained on Permanent Pathology for the Classification of Squamous Cell Carcinoma in Mohs Frozen Sections: Lessons Learned
Choudhary, Anirudh , Nassir, Shams , Yousif, Miranda , Hughes, Alysia , Kechter, Jacob , Leibovit-Reiben, Zachary , Stockard, Alyssa , Vidal, Nahid Y. , Rios-Duarte, Jorge A, Kechter, Jacob A, Rios‐Duarte, Jorge A. , Iyer, Ravishankar K. , Leibovit‐Reiben, Zachary , Mangold, Aaron R.

Mayo Clinic

Dermatologic Surgery | July 9, 2025 | Volume: 52 | Issue: 1 | Pages: 31-35

10.1097/dss.0000000000004758 | PMID 40631753 Get It

BACKGROUND There is a scarcity of artificial intelligence models trained on frozen pathology. One way to expand the clinical utility of models trained on permanent pathology is by applying them to frozen sections and fine-tune based on weaknesses. OBJECTIVE To qualitatively evaluate a deep learning model trained on permanent pathology to classify squamous cell carcinoma on Mohs surgery frozen sections to learn model shortcomings and inform retraining and fine-tuning. MATERIALS AND METHODS The authors trained a model for classification of tumor on 746 skin biopsy slides and tested it on 15 Mohs surgery frozen sections. The authors estimated performance metrics and compared the regions of interest generated by the model with the original H&E slides. RESULTS The model achieved an AUC-ROC of 0.985 and 0.796 for tumor classification in permanent pathology and in frozen sections, respectively. Regions of interest for frozen sections with scarce tumor areas were inaccurate, focusing on normal tissue for slides classified as false negative, or highlighting structures different from tumor (e.g., inflammation, muscle, and nerves) for slides classified as true positive. CONCLUSION Deep anatomical structures more commonly present in Mohs frozen pathology might represent data out-of-distribution for models trained on permanent pathology, potentially leading to inadequate model outputs.
Retrieval Augmented Generation–Enabled Large Language Model for Risk Stratification of Cutaneous Squamous Cell Carcinoma
Jairath, Neil , Cheraghlou, Shayan , Criscito, Maressa C. , Leibovit-Reiben, Zachary , Stockard, Alyssa , Doudican, Nicole , Mangold, Aaron R. , Stockard, Alyssa , Mangold, Aaron, Mangold, A R , Pahalyants, Vartan , Maas, Derek , Lee, Nayoung , Stevenson, Mary L. , Mehta, Apoorva , Leibovit‐Reiben, Zachary , Carucci, John A.

Mayo Clinic

JAMA Dermatology | June 11, 2025 | Volume: 161 | Issue: 8 | Pages: 796

10.1001/jamadermatol.2025.1614 | PMID 40498504 Get It

ImportanceThere exists substantial heterogeneity in outcomes within T stages for patients with cutaneous squamous cell carcinoma (cSCC).ObjectiveTo determine whether a customized generative pretrained transformer model, trained on a comprehensive dataset with more than 1 trillion parameters and equipped with relevant focused context and retrieval augmented generation (RAG), could excel in aggregating and interpreting vast quantities of data to develop a novel class-based risk stratification system that outperforms the current standards.Design, Setting, and ParticipantsTo build the RAG knowledge base, a systematic review of the literature was conducted that addressed risk factors for poor outcomes in cSCC. Using the RAG-enabled generative pretrained transformer (GPT) model, we developed a novel class-based risk stratification system that assigned point values for risk factors, culminating in a GPT-based prognostication system called the artificial intelligence–derived risk score (AIRIS). The system’s performance was validated on a combined prospective and retrospective cohort of 2379 primary cSCC tumors (1996-2023) with at least 36 months of follow-up, against Brigham and Women’s Hospital (BWH) and American Joint Committee on Cancer Staging Manual, eighth edition (AJCC8) systems in stratifying risk for locoregional recurrence (LR), nodal metastasis (NM), distant metastasis (DM), and disease-specific death (DSD).Main Outcomes and MeasuresPerformance metrics evaluated included distinctiveness, homogeneity, and monotonicity, as defined by the AJCC8, as well as sensitivity, specificity, positive predictive value, negative predictive value, accuracy, the area under the receiver operating characteristic curve, and concordance.ResultsThe median age at diagnosis was 73 (IQR, 64-81) years, with 38.5% female patients and 61.5% male patients. The AIRIS prognostication system demonstrated superior sensitivity across all outcomes (LR, 49.1%; NM, 73.7%; DM, 82.5%; and DSD, 72.2%) and the highest area under the receiver operating characteristic curve values (LR, 0.69; NM, 0.81; DM, 0.85; and DSD, 0.80), indicating significantly enhanced discriminative capability compared with the BWH and AJCC8 systems. While all systems were comparably distinctive, the AIRIS prognostication system consistently demonstrated the lowest proportion of tumors exhibiting poor outcomes in low-risk categories, suggesting its improved homogeneity and monotonicity.Conclusions and RelevanceThe results of this diagnostic study suggest that the AIRIS system outperforms the existing BWH and AJCC8 prognostication systems, potentially providing a more effective tool for predicting poor outcomes in cSCC. This study illustrates the potential of large language models in refining prognostic tools, offering implications for treating patients with cancer.